275 related articles for article (PubMed ID: 34069899)
1. Effects of (a Combination of) the Beta
Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
Cells; 2021 May; 10(5):. PubMed ID: 34069899
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
[TBL] [Abstract][Full Text] [Related]
4. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
Blais CM; Davis BE; Cockcroft DW
Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
[TBL] [Abstract][Full Text] [Related]
5. Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.
Baroffio M; Barisione G; Brusasco V
Respir Res; 2017 Jul; 18(1):145. PubMed ID: 28754132
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
8. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
9. Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
Aritake H; Tamada T; Murakami K; Gamo S; Nara M; Kazama I; Ichinose M; Sugiura H
Pflugers Arch; 2021 Jun; 473(6):883-896. PubMed ID: 34031755
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
11. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Rossi A; Zanardi E; Poletti V; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
13. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
15. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
16. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Pelaia G; Maselli R; Matera MG
Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
[TBL] [Abstract][Full Text] [Related]
18. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA
Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]